Seattle Genetics to Present on ADC Technology at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.BOTHELL, Wash. -- Two ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. Collaborators Also Scheduled to Report Preclinical Data Seattle Genetics, Inc. (Nasdaq: SGEN SGEN Signal/System Generator ) today announced that it will report preclinical advances with its antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the Pennsylvania Convention Center The Pennsylvania Convention Center is a multi-use public facility in Philadelphia, Pennsylvania which is designed to accommodate conventions, exhibitions, conferences and other events. in Philadelphia. In addition, two of Seattle Genetics' collaborators, CuraGen and MedImmune, will make presentations regarding their ADC programs utilizing Seattle Genetics' technology. "We are continuing to make significant strides with our ADC technology, which we employ in our own product pipeline, including SGN-35 and SGN-75, as well as license to leading biotechnology and pharmaceutical companies," stated Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "The presentations at this conference by Seattle Genetics and our collaborators demonstrate some of the key advances being made with our technology to empower the next generation of targeted cancer therapies." New Monoclonal Antibody-Auristatin Conjugates: Design of Novel Linkers for Targeted Drug Delivery Scientists began to study targeted drug delivery, because the traditional drug delivery system had many disadvantages, such as high toxic effect and high minimum effective dose. In traditional drug delivery system, after the patient takes some drugs, the drugs will be all over his body (Abstract A60; November 15, 2005; 12:30-2:30 p.m. and 5:30-7:30 p.m., Hall C) ADCs are monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). linked to potent cell-killing drugs. Due to the targeting ability of monoclonal antibodies, ADCs are capable of delivering a cell-killing payload (1) Refers to the "actual data" in a packet or file minus all headers attached for transport and minus all descriptive meta-data. In a network packet, headers are appended to the payload for transport and then discarded at their destination. directly to a tumor cell, while minimizing toxicity to healthy cells. Seattle Genetics has developed improved ADC technology utilizing stable, enzyme-cleavable linkers to deliver synthetic, highly-potent cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic payloads. The linkers are stable in the bloodstream and release the drug payload once inside target cells. In this poster presentation, the company will describe the properties of one of its cell-killing drug payloads, monomethyl auristatin F (MMAF MMAF Modified Motorcycle Association of Finland MMAF monomethyl auristatin phenylalanine ). ADCs utilizing MMAF were designed to transport the drug into target cells, resulting in a highly potent agent compared to free drug in certain preclinical models. In addition, the poster includes data on a series of ADCs in which various linker components were altered or deleted. The findings suggest that modifications to the linker can lead to new ADCs with improved therapeutic indices. ADC Collaborator Presentations In addition, two of Seattle Genetics' ADC collaborators will present the following abstracts during poster sessions: --CuraGen Corporation --"Treatment parameters modulating regression of human melanoma xenografts in situ In place. When something is "in situ," it is in its original location. by an antibody-drug conjugate (CR011-vcMMAE) targeting gpNMB-expressing tumor cells" (Abstract A70) --MedImmune Inc. --"Targeting of EphA2 on tumor cells with antibodies conjugated conjugated adj. Conjugate. estrogens, conjugated Warning - Hazardous drug! C.E.S. to monomethyl auristatin F" (Abstract B75) About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting clinical and preclinical development of a diverse portfolio of product candidates in a variety of oncology and immunology settings. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com. Certain of the statements made in this press release are forward-looking, such as those, among others, relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the continued progress and recent advances of Seattle Genetics' ADC technology. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our ADC product candidates, as well as our collaborators', move into clinical trials and the risks inherent in early stage development. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion